glp-1 and muscle mass Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia Sarcopenic Obesity | Current Nutrition Reports GLP-1 Weight Loss Risks: Muscle

10.1002/dc.24895 50

^In a multi-national, double-blind clinical trial of over 17,000 patients with BMI of 27 or greater, weekly injections of semaglutide for a mean duration of 33 months reduced the risk of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke by 20%

GLP-1 agonists are prescription medications that mimic glucagon-like peptide-1, a natural hormone your intestines release after you eat

Drug injury cases can lead to payment for medical bills, past and future lost wages, loss of earning ability, pain and suffering, emotional distress, disability, disfigurement, and long-term care or monitoring costs

A separate 2024 study reached a similar conclusion and credited the hydrating benefits to its film-forming properties